STOCK TITAN

Paratek Pharmaceuticals Inc. - PRTK STOCK NEWS

Welcome to our dedicated news page for Paratek Pharmaceuticals (Ticker: PRTK), a resource for investors and traders seeking the latest updates and insights on Paratek Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Paratek Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Paratek Pharmaceuticals's position in the market.

Rhea-AI Summary
Paratek Pharmaceuticals announces new data presentations at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Gurnet Point Capital and Novo Holdings complete acquisition of Paratek Pharmaceuticals for $462 million, including assumption of debt. Stockholders to receive $2.15 per share in cash and $0.85 per share as Contingent Value Right upon achieving $320 million in U.S. NUZYRA net sales by 2026. Paratek to be delisted from NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Paratek Pharmaceuticals announces stockholders' approval of merger agreement proposal
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
acquisition
Rhea-AI Summary
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) reported $33.8 million in NUZYRA net U.S. sales, a 35% increase from Q2 2022, and announced an acquisition agreement with Gurnet Point Capital and Novo Holdings A/S. The company also highlighted a BARDA contract modification and a positive opinion for orphan medicinal product designation for NUZYRA for the treatment of NTM lung disease in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
earnings
-
Rhea-AI Summary
Paratek Pharmaceuticals announced that it has filed definitive proxy materials and a letter to stockholders in connection with its acquisition by Gurnet Point Capital and Novo Holdings. Stockholders will receive an upfront cash payment of $2.15 per share and a contingent value right of $0.85 per share upon the achievement of a commercial milestone, resulting in a total potential value of $3.00 per share. The special meeting of stockholders will be held on September 18, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
acquisition
-
Rhea-AI Summary
NexPoint Event Driven Fund demands access to all records to investigate potential breach of fiduciary duty by Paratek Pharmaceuticals' board of directors in relation to the proposed acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
acquisition
Rhea-AI Summary
Paratek Pharmaceuticals announces modification to its Project BioShield contract with BARDA for the development of NUZYRA anthrax treatment. The next procurement will be split into two based on specific development milestones. Positive top-line data expected in Q1 2024 and Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
Paratek Pharmaceuticals Inc.

Nasdaq:PRTK

PRTK Rankings

PRTK Stock Data

127.83M
50.11M
11.7%
55.08%
4.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About PRTK

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.